Methylprednisolone suleptanate Pharmacia Corp

Area of Science:

• Pharmacology
• Immunology
• Pulmonology

Background:

• Methylprednisolone suleptanate (Promedrol) is a prodrug of methylprednisolone developed for asthma treatment.
• It has received approval in Switzerland and is under review in other countries.
• Preliminary data suggests potential for intravenous treatment of immunological diseases.

Purpose of the Study:

• To evaluate the anti-inflammatory and bronchodilatory effects of methylprednisolone suleptanate.
• To assess the efficacy and safety of Promedrol pulse therapy in lupus nephritis patients.
• To explore its potential in treating nephritis, hypotension, and spinal cord injury.

Main Methods:

• Preclinical studies in mice, rats, and guinea pigs demonstrated anti-inflammatory/bronchodilatory effects.
• Phase II clinical trial assessed efficacy and safety of Promedrol pulse therapy in lupus nephritis patients.
• Studies in lupus patients evaluated tolerability and efficacy in delaying CNS symptoms in SLE.

Main Results:

• Demonstrated anti-inflammatory and bronchodilatory effects in animal models.
• Phase II trial showed efficacy and safety of Promedrol pulse therapy for lupus nephritis.
• Doses up to 1000 mg/day were well tolerated in lupus patients.
• Pulse therapy (400-800 mg/day) showed efficacy in delaying CNS symptoms in SLE patients.

Conclusions:

• Methylprednisolone suleptanate (Promedrol) exhibits significant anti-inflammatory and bronchodilatory properties.
• It is effective and safe for treating lupus nephritis and potentially managing CNS symptoms in SLE.
• Further preclinical studies are investigating its use for spinal cord injury.